Email this article 
THE PREDICTION OF ATRIAL FIBRILLATION IN PATIENTS WITH ARTERIAL HYPERTENSION
- Authors: Grigoriadi N.E.1, Vasilets L.M.2, Tuev A.V.2, Ratanova E.A.2, Khlynova O.V.2, Agafonov A.V.2
-
Affiliations:
- Perm Regional Clinical Hospital, Russian Federation
- Perm State Medical Academy n.a. E.A. Wagner, Russian Federation
- Issue: Vol 68, No 11 (2013)
- Pages: 26-29
- Section: CARDIOLOGY: CURRENT ISSUES
- URL: https://vestnikramn.spr-journal.ru/jour/article/view/118
- DOI: https://doi.org/10.15690/vramn.v68i11.839
- ID: 118
Cite item
Full Text
Abstract
Aim. To study the parameters of the structural and functional state of the myocardium in patients with hypertension, to determine their prognostic value on the risk of atrial fibrillation (AF). Patients and methods: the study involved 72 people: patients with hypertension and AF, with isolated hypertension and apparently healthy individuals. All of them performed echocardiography, blood pressure monitoring and monitoring of cardiogram. Results: the dilatation of left atrial was founded: patients with the atrial fibrillation on the background of hypertension observed the most pronounced changes in the left atrial. In patients with hypertension without arrhythmias and in combination with atrial fibrillation severe left ventricular hypertrophy was observed. Left ventricle systolic function in groups has been stored but in patients with atrial fibrillation on the background of hypertension was significantly lower. The risk of atrial fibrillation in patients with hypertension prognostic value are the only values of the age, the volume index of the left atrial to the body surface area and left ventricular ejection fraction. Conclusions. The risk of AF in hypertension occurs over the age of 55 and each subsequent year increases it in 1,2 times, it increases with an index value of the left atrial to the body surface over 29 ml/m2 and with a decrease in left ventricular ejection fraction less than 58%.
About the authors
N. E. Grigoriadi
Perm Regional Clinical Hospital, Russian Federation
Author for correspondence.
Email: grigoriadinata@mail.ru
MD, cardiologist certificated by highest qualification grade of Cardiological Department of Perm Regional Clinical Hospital. Address: office 215, 85, Pushkin Street, Perm, RF, 614080, tel.: (342) 239-29-08 Russian Federation
L. M. Vasilets
Perm State Medical Academy n.a. E.A. Wagner, Russian Federation
Email: grigoriadinata@mail.ru
PhD, professor of the Department of Clinical Therapy № 1 of E.A. Vagner Perm State Medical Academy. Address: office 322, 85, Pushkin Street, Perm, RF, 614080, tel.: +7 (342) 239-29-08 Russian Federation
A. V. Tuev
Perm State Medical Academy n.a. E.A. Wagner, Russian Federation
Email: grigoriadinata@mail.ru
Honoured Scientist of Russian Federation, PhD, Head of the Department of Clinical Therapy № 1 of E.A. Vagner Perm State Medical Academy. Address: office 721, 85, Pushkin Street, Perm, RF, 614080, tel.: +7 (342) 239-31-97 Russian Federation
E. A. Ratanova
Perm State Medical Academy n.a. E.A. Wagner, Russian Federation
Email: lena.ratanova@mail.ru
postgraduate of the Department of Clinical Therapy № 1 of E.A. Vagner Perm State Medical Academy. Address: office 216, 85, Pushkin Street, Perm, RF, 614080, tel.: +7 (342) 2392908 Russian Federation
O. V. Khlynova
Perm State Medical Academy n.a. E.A. Wagner, Russian Federation
Email: olgakhlynova@mail.ru
PhD, professor of the Department of Clinical Therapy № 1 of E.A. Vagner Perm State Medical Academy. Address: office 728, 85, Pushkin Street, Perm, RF, 614080, tel.: +7 (342) 239-29-08 Russian Federation
A. V. Agafonov
Perm State Medical Academy n.a. E.A. Wagner, Russian Federation
Email: a.agafonov@list.ru
PhD, professor of the Department of Clinical Therapy № 1 of E.A. Vagner Perm State Medical Academy. Address: office 216, 85, Pushkin Street, Perm, RF, 614080, tel.: +7 (342) 2392908 Russian Federation
References
- Savelieva I., Kourliouros A., Camm J. Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. Naunyn Schmiedebergs Arch. Pharmacol. 2010; 381 (3): 1–13.
- Filatov A.G., Tarashvili E.G. Ann. aritmol = Annals of arrhythmology. 2012; 2: 5–13.
- Volkov V.E., Babaev F.Z., Khezheva F.M., Pshenitsyn A.I., Mazur N.A. Vrach = The Doctor. 2008; 3: 19–23.
- Pinto A., Tuttolomondo A., Casuccio A., Di Raimondo D., Di Sciacca R., Arnao V., Licata G. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF). Clin. Sci. (London). 2009; 116: 781–789.
- Schnabel R. Can we predict the occurrence of atrial fibrillation? Clin. Cardiol. 2012; 35 (Suppl. 1): 5–9.
- Tatarskii B.A., Vorob'ev I.V. Vestn. aritmol = Bulletin of arrhythmology. 2005; 41: 39–46.
- Aldhoon B., Melenovský V., Peichl P., Kautzner J. New insights into mechanisms of atrial fibrillation. Physiol. Res. 2010; 59 (1): 1–12.
- Baranova E.I. Arterial'naya gipertenziya = Arterial hypertension. 2011; 17(4): 293–304.
- Healey J., Connolly S. Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. Am. J. Cardiol. 2003; 91 (10A): 9–14.
- Go O., Rosendorff C. Hypertension and atrial fibrillation. Curr. Cardiol. Rep. 2009; 11 (6): 430–435.
Supplementary files
